Open Access. Powered by Scholars. Published by Universities.®
- Institution
- Keyword
-
- Adoptive Transfer (1)
- Animals (1)
- Antigen (1)
- CD8-Positive T-Lymphocytes (1)
- Cancer Vaccines (1)
-
- Cell Line (1)
- Cell Line, Tumor (1)
- Cellular (1)
- Cytotoxicity (1)
- Cytotoxicity, Immunologic (1)
- Department of Medicine (1)
- Department of Medicine Faculty (1)
- Department of Pathology and Laboratory Medicine (1)
- Experimental (1)
- Gelatinases (1)
- Genetic (1)
- Immunity (1)
- Immunity, Cellular (1)
- Immunologic (1)
- Inbred BALB C (1)
- Inbred C57BL (1)
- Leishmania donovani bodies (1)
- Membrane Proteins (1)
- Mice (1)
- Mice, Inbred BALB C (1)
- Mice, Inbred C57BL (1)
- Neoplasm Transplantation (1)
- Neoplasms (1)
- Neoplasms, Experimental (1)
- Phlebotomus (1)
- Publication
- Publication Type
Articles 1 - 8 of 8
Full-Text Articles in Pathology
Leishmania Donovani Bodies In Bone Marrow, Natasha Ali, Shabneez Hussain
Leishmania Donovani Bodies In Bone Marrow, Natasha Ali, Shabneez Hussain
Department of Pathology and Laboratory Medicine
We report a case of a 5-year-old female, resident of Afghanistan, who presented with fever and massive splenomegaly. Bone marrow revealed Leishmania donovani bodies (LD bodies) in macrophages characterized by a kinetoplast and characteristic double dot appearance. She was diagnosed as visceral leishmaniasis which is transmitted by sandflies (Phlebotomus).
Thrombospondin-1 Signaling Mechanisms Regulating Pigment Epithelium-Derived Factor Expression And Lipolytic Activity In Prostate Cancer, Nizar Khamjan
Thrombospondin-1 Signaling Mechanisms Regulating Pigment Epithelium-Derived Factor Expression And Lipolytic Activity In Prostate Cancer, Nizar Khamjan
Theses and Dissertations
Background: Prostate cancer (PCa) is the most common cancer that occurs in men in the United States. To grow, tumors need to induce new blood vessels growth, a process called angiogenesis. Thus, tumors down regulate molecules that inhibit this process. Two such molecules that are down-regulated in PCa are thrombospondin-1 (TSP-1) and pigment epithelium-derived factor (PEDF). Interestingly, both of these proteins also function in regulating lipid metabolism. Our lab has data to suggest that TSP-1 induces PEDF expression and lipid catabolism (lipolysis), the hydrolysis of triglycerides into fatty acids and a glycerol, in PCa cells; however, the molecular pathway of …
Lymphoma Masquerading As Pneumonia With Acute Renal Failure: A Rare Clinical And Radiological Presentation Of Diffuse Large B Cell Gastric Lymphoma (Dlbcl), Ranjit R. Nair Md, Cheryl A. Bloomfield Md, Sharif A. Ali Md, Stacey Smith Md, Facp
Lymphoma Masquerading As Pneumonia With Acute Renal Failure: A Rare Clinical And Radiological Presentation Of Diffuse Large B Cell Gastric Lymphoma (Dlbcl), Ranjit R. Nair Md, Cheryl A. Bloomfield Md, Sharif A. Ali Md, Stacey Smith Md, Facp
Department of Medicine
No abstract provided.
Carp-1 Functional Mimetics Are A Novel Class Of Small Molecule Inhibitors Of Malignant Pleural Mesothelioma Cells, Shazia Jamal, Vino T. Cheriyan, Magesh Muthu, Sara Munie, Edi Levi, Abdelkader E. Ashour, Harvey I. Pass, Anil Wali, Mandip Singh, Arun K. Rishi
Carp-1 Functional Mimetics Are A Novel Class Of Small Molecule Inhibitors Of Malignant Pleural Mesothelioma Cells, Shazia Jamal, Vino T. Cheriyan, Magesh Muthu, Sara Munie, Edi Levi, Abdelkader E. Ashour, Harvey I. Pass, Anil Wali, Mandip Singh, Arun K. Rishi
Oncology Faculty Publications
Malignant pleural mesothelioma (MPM) is an asbestos-related thoracic malignancy that is characterized by late metastases, and resistance to therapeutic modalities. The toxic side-effects of MPM therapies often limit their clinical effectiveness, thus necessitating development of new agents to effectively treat and manage this disease in clinic. CARP-1 functional mimetics (CFMs) are a novel class of compounds that inhibit growth of diverse cancer cell types. Here we investigated MPM cell growth suppression by the CFMs and the molecular mechanisms involved. CFM-1, -4, and -5 inhibited MPM cell growth, in vitro, in part by stimulating apoptosis. Apoptosis by CFM-4 involved activation of …
Natural History Of Untreated Prostate Specific Antigen Radiorecurrent Prostate Cancer In Men With Favorable Prognostic Indicators, Andrew Renshaw
Natural History Of Untreated Prostate Specific Antigen Radiorecurrent Prostate Cancer In Men With Favorable Prognostic Indicators, Andrew Renshaw
All Publications
No abstract provided.
Targeting Fibroblast Activation Protein In Tumor Stroma With Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth And Augment Host Immunity Without Severe Toxicity., Liang-Chuan S. Wang, Albert Lo, John Scholler, Jing Sun, Rajrupa S. Majumdar, Veena Kapoor, Michael Antzis, Cody E. Cotner, Laura A. Johnson, Amy C. Durham, Charalambos C. Solomides, Md, Carl H. June, Ellen Puré, Steven M. Albelda
Targeting Fibroblast Activation Protein In Tumor Stroma With Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth And Augment Host Immunity Without Severe Toxicity., Liang-Chuan S. Wang, Albert Lo, John Scholler, Jing Sun, Rajrupa S. Majumdar, Veena Kapoor, Michael Antzis, Cody E. Cotner, Laura A. Johnson, Amy C. Durham, Charalambos C. Solomides, Md, Carl H. June, Ellen Puré, Steven M. Albelda
Department of Pathology, Anatomy, and Cell Biology Faculty Papers
The majority of chimeric antigen receptor (CAR) T-cell research has focused on attacking cancer cells. Here, we show that targeting the tumor-promoting, nontransformed stromal cells using CAR T cells may offer several advantages. We developed a retroviral CAR construct specific for the mouse fibroblast activation protein (FAP), comprising a single-chain Fv FAP [monoclonal antibody (mAb) 73.3] with the CD8α hinge and transmembrane regions, and the human CD3ζ and 4-1BB activation domains. The transduced muFAP-CAR mouse T cells secreted IFN-γ and killed FAP-expressing 3T3 target cells specifically. Adoptively transferred 73.3-FAP-CAR mouse T cells selectively reduced FAP(hi) stromal cells and inhibited the …
Metabotropic Glutamate Receptor-1 Contributes To Progression In Triple Negative Breast Cancer, Malathi Banda, Cecilia L. Speyer, Sara N. Semma, Kingsley O. Osuala, Nicole Kounalakis, Keila E. Torres Torres, Nicola J. Barnard, Hyunjin J. Kim, Bonnie F. Sloane, Fred R. Miller, James S. Goydos, David H. Gorski
Metabotropic Glutamate Receptor-1 Contributes To Progression In Triple Negative Breast Cancer, Malathi Banda, Cecilia L. Speyer, Sara N. Semma, Kingsley O. Osuala, Nicole Kounalakis, Keila E. Torres Torres, Nicola J. Barnard, Hyunjin J. Kim, Bonnie F. Sloane, Fred R. Miller, James S. Goydos, David H. Gorski
Department of Surgery
TNBC is an aggressive breast cancer subtype that does not express hormone receptors (estrogen and progesterone receptors, ER and PR) or amplified human epidermal growth factor receptor type 2 (HER2), and there currently exist no targeted therapies effective against it. Consequently, finding new molecular targets in triple negative breast cancer (TNBC) is critical to improving patient outcomes. Previously, we have detected the expression of metabotropic glutamate receptor-1 (gene: GRM1; protein: mGluR1) in TNBC and observed that targeting glutamatergic signaling inhibits TNBC growth both in vitro and in vivo. In this study, we explored how mGluR1 contributes to TNBC …
Gold(Iii)-Dithiocarbamato Peptidomimetics In The Forefront Of The Targeted Anticancer Therapy: Preclinical Studies Against Human Breast Neoplasia, Chiara Nardon, Sara M. Schmitt, Huanjie Yang, Jian Zuo, Delores Fregona, Q. Ping Dou
Gold(Iii)-Dithiocarbamato Peptidomimetics In The Forefront Of The Targeted Anticancer Therapy: Preclinical Studies Against Human Breast Neoplasia, Chiara Nardon, Sara M. Schmitt, Huanjie Yang, Jian Zuo, Delores Fregona, Q. Ping Dou
Oncology Faculty Publications
Since the serendipitous discovery of cisplatin, platinum-based drugs have become well-established antitumor agents, despite the fact that their clinical use is limited by many severe side-effects. In order to both improve the chemotherapeutic index and broaden the therapeutic spectrum of current drugs, our most recent anti-neoplastic agents, Au(III) complexes, were designed as carrier-mediated delivery systems exploiting peptide transporters, which are up-regulated in some cancers. Among all, we focused on two compounds and tested them on human MDA-MB-231 (resistant to cisplatin) breast cancer cell cultures and xenografts, discovering the proteasome as a major target both in vitro and in vivo. …